Clinical Trial News
We previously announced positive data from our Phase 2a and Phase 2b clinical trials of reproxalap ophthalmic solution in allergic conjunctivitis. The results show that reproxalap clinically improved ocular itching in patients with allergic conjunctivitis.
In March 2019, we announced positive phase 3 results from the ALLEVIATE Trial for allergic conjunctivitis. In the second half of 2019, we plan to meet with regulatory authorities to discuss the ALLEVIATE clinical trial results and remaining clinical requirements for a potential submission of a New Drug Application to the U.S. Food and Drug Administration.